Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Vivani Medical ( (VANI) ) has issued an announcement.
The 2025 Annual Meeting of Stockholders of Vivani Medical, Inc. was held on June 24, 2025, with a quorum present. During the meeting, stockholders elected six directors to the Board, ratified BPM LLP as the independent auditor for 2025, and approved executive compensation on a non-binding advisory basis.
The most recent analyst rating on (VANI) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Vivani Medical stock, see the VANI Stock Forecast page.
Spark’s Take on VANI Stock
According to Spark, TipRanks’ AI Analyst, VANI is a Neutral.
Vivani Medical’s overall score reflects its challenging financial situation and unfavorable valuation. Despite some positive corporate events and neutral technical indicators, the company’s consistent losses and reliance on external financing weigh heavily on the score. The strategic focus on core drug implant business and recent milestones offer some potential for improvement, but substantial operational and financial efficiency improvements are necessary for a stronger outlook.
To see Spark’s full report on VANI stock, click here.
More about Vivani Medical
Average Trading Volume: 111,120
Technical Sentiment Signal: Hold
Current Market Cap: $74.65M
See more insights into VANI stock on TipRanks’ Stock Analysis page.